These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 25072603)

  • 1. Use of the piggyBac transposon to create stable packaging cell lines for the production of clinical-grade self-inactivating γ-retroviral vectors.
    Feldman SA; Xu H; Black MA; Park TS; Robbins PF; Kochenderfer JN; Morgan RA; Rosenberg SA
    Hum Gene Ther Methods; 2014 Aug; 25(4):253-60. PubMed ID: 25072603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new PG13-based packaging cell line for stable production of clinical-grade self-inactivating gamma-retroviral vectors using targeted integration.
    Loew R; Meyer Y; Kuehlcke K; Gama-Norton L; Wirth D; Hauser H; Stein S; Grez M; Thornhill S; Thrasher A; Baum C; Schambach A
    Gene Ther; 2010 Feb; 17(2):272-80. PubMed ID: 19865181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simple viral/minimal piggyBac hybrid vectors for stable production of self-inactivating gamma-retroviruses.
    Troyanovsky B; Bitko V; Fouty B; Solodushko V
    BMC Res Notes; 2015 Aug; 8():379. PubMed ID: 26306622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HEK293-based production platform for γ-retroviral (self-inactivating) vectors: application for safe and efficient transfer of COL7A1 cDNA.
    Hennig K; Raasch L; Kolbe C; Weidner S; Leisegang M; Uckert W; Titeux M; Hovnanian A; Kuehlcke K; Loew R
    Hum Gene Ther Clin Dev; 2014 Dec; 25(4):218-28. PubMed ID: 25381930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficient human hematopoietic cell transduction using RD114- and GALV-pseudotyped retroviral vectors produced in suspension and serum-free media.
    Ghani K; Wang X; de Campos-Lima PO; Olszewska M; Kamen A; Rivière I; Caruso M
    Hum Gene Ther; 2009 Sep; 20(9):966-74. PubMed ID: 19453219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficient construction of producer cell lines for a SIN lentiviral vector for SCID-X1 gene therapy by concatemeric array transfection.
    Throm RE; Ouma AA; Zhou S; Chandrasekaran A; Lockey T; Greene M; De Ravin SS; Moayeri M; Malech HL; Sorrentino BP; Gray JT
    Blood; 2009 May; 113(21):5104-10. PubMed ID: 19286997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Scale-up and manufacturing of clinical-grade self-inactivating γ-retroviral vectors by transient transfection.
    van der Loo JC; Swaney WP; Grassman E; Terwilliger A; Higashimoto T; Schambach A; Baum C; Thrasher AJ; Williams DA; Nordling DL; Reeves L; Malik P
    Gene Ther; 2012 Mar; 19(3):246-54. PubMed ID: 21753795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation of retroviral vector for clinical studies using transient transfection.
    Yang S; Delgado R; King SR; Woffendin C; Barker CS; Yang ZY; Xu L; Nolan GP; Nabel GJ
    Hum Gene Ther; 1999 Jan; 10(1):123-32. PubMed ID: 10022537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reliable generation of stable high titer producer cell lines for gene therapy.
    Rattmann I; Kleff V; Feldmann A; Ludwig C; Sorg UR; Opalka B; Moritz T; Flasshove M
    Intervirology; 2007; 50(3):197-203. PubMed ID: 17283445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Large-scale manufacturing of safe and efficient retrovirus packaging lines for use in immunotherapy protocols.
    Farson D; McGuinness R; Dull T; Limoli K; Lazar R; Jalali S; Reddy S; Pennathur-Das R; Broad D; Finer M
    J Gene Med; 1999; 1(3):195-209. PubMed ID: 10738568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new generation of retroviral producer cells: predictable and stable virus production by Flp-mediated site-specific integration of retroviral vectors.
    Schucht R; Coroadinha AS; Zanta-Boussif MA; Verhoeyen E; Carrondo MJ; Hauser H; Wirth D
    Mol Ther; 2006 Aug; 14(2):285-92. PubMed ID: 16697259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disclosing the Parameters Leading to High Productivity of Retroviral Producer Cells Lines: Evaluating Random Versus Targeted Integration.
    Bandeira VS; Tomás HA; Alici E; Carrondo MJ; Coroadinha AS
    Hum Gene Ther Methods; 2017 Apr; 28(2):78-90. PubMed ID: 28301970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Packaging cell line characteristics and optimizing retroviral vector titer: the National Gene Vector Laboratory experience.
    Reeves L; Smucker P; Cornetta K
    Hum Gene Ther; 2000 Oct; 11(15):2093-103. PubMed ID: 11044911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An improved method for generating retroviral producer clones for vectors lacking a selectable marker gene.
    Persons DA; Mehaffey MG; Kaleko M; Nienhuis AW; Vanin EF
    Blood Cells Mol Dis; 1998 Jun; 24(2):167-82. PubMed ID: 9642098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Construction and application of retroviral vector system useful for high-efficiency transfection into human T cells].
    Zhang RP; Yun L; Peng L; Lu B; Zhou Q; Wang H; Guo YJ
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2006 Jul; 22(4):420-2, 426. PubMed ID: 16805997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of High-Titer Self-Inactivated γ-Retroviral Vector Producer Cells.
    Ghani K; Boivin-Welch M; Roy S; Dakiw-Piaceski A; Barbier M; Pope E; Germain L; Caruso M
    Mol Ther Methods Clin Dev; 2019 Sep; 14():90-99. PubMed ID: 31312667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Green fluorescent protein retroviral vectors: low titer and high recombination frequency suggest a selective disadvantage.
    Hanazono Y; Yu JM; Dunbar CE; Emmons RV
    Hum Gene Ther; 1997 Jul; 8(11):1313-9. PubMed ID: 9295126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Production of lentiviral vectors for transducing cells from the central nervous system.
    Li M; Husic N; Lin Y; Snider BJ
    J Vis Exp; 2012 May; (63):e4031. PubMed ID: 22664962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of a high-titer packaging cell line for the production of retroviral vectors in suspension and serum-free media.
    Ghani K; Cottin S; Kamen A; Caruso M
    Gene Ther; 2007 Dec; 14(24):1705-11. PubMed ID: 17928873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Large-scale clinical-grade retroviral vector production in a fixed-bed bioreactor.
    Wang X; Olszewska M; Qu J; Wasielewska T; Bartido S; Hermetet G; Sadelain M; Rivière I
    J Immunother; 2015 Apr; 38(3):127-35. PubMed ID: 25751502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.